Author

José Manuel Benítez

INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SOUTHERN SPAIN (ANDALUSIA)
INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SOUTHERN SPAIN (ANDALUSIA)

José Manuel Benítez  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

José Manuel Benítez  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

José Manuel Benítez  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

José Manuel Benítez  et al.

EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU
EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU

José Manuel Benítez  et al.

INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU
INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU

José Manuel Benítez  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

José Manuel Benítez  et al.

BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU
BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU

José Manuel Benítez  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

José Manuel Benítez  et al.

Item 1 - 9 / 9
1